Literature DB >> 3323415

Comparison of two commercially available anti-HIV ELISAs: Abbott HTLV III EIA and Du Pont HTLV III-ELISA.

U Burkhardt1, T Mertens, H J Eggers.   

Abstract

Serum specimens were tested for HIV antibodies by two commercially available ELISAs (Abbott HTLV III EIA and Du Pont HTLV III-ELISA). The specificity and sensitivity of these assays were determined by comparison with indirect immunofluorescence and Western blot analysis. Specificity ranged from 94.3% in the Abbott assay to 97.9% in the Du Pont-ELISA. The sensitivity was 100% in the Abbott-ELISA and 99% in the Du Pont test. With both tests, false-positive results occurred predominantly in sera from patients with immunological disorders (kidney transplant recipients, lymphoma, Stevens-Johnson syndrome, etc.), whereas symptomatic AIDS-patients, patients with ARC, and persons with a defined risk for HIV infection could be diagnosed unequivocally. Specificity and sensitivity of anti-HIV ELISAs seemed to depend not only on definition of the cutoff value but also on other factors, such as antigen preparation and inactivation measures. Testing of ELISA-reactive sera by confirmatory tests remains necessary.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3323415     DOI: 10.1002/jmv.1890230303

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  4 in total

1.  Sensitivity and specificity of pooled versus individual sera in a human immunodeficiency virus antibody prevalence study.

Authors:  B Cahoon-Young; A Chandler; T Livermore; J Gaudino; R Benjamin
Journal:  J Clin Microbiol       Date:  1989-08       Impact factor: 5.948

2.  Comparison of five commercial enzyme-linked immunosorbent assays and Western immunoblotting for human immunodeficiency virus antibody detection in serum samples from Central Africa.

Authors:  F Behets; A Disasi; R W Ryder; K Bishagara; P Piot; M Kashamuka; M Kamenga; N Nzila; M Laga; G Vercauteren
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

3.  Multicenter evaluation of a fully automated screening test, VIDAS HIV 1 + 2, for antibodies to human immunodeficiency virus types 1 and 2.

Authors:  J M Azevedo-Pereira; M H Lourenço; F Barin; R Cisterna; F Denis; P Moncharmont; R Grillo; M O Santos-Ferreira
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

4.  Why the C-statistic is not informative to evaluate early warning scores and what metrics to use.

Authors:  Santiago Romero-Brufau; Jeanne M Huddleston; Gabriel J Escobar; Mark Liebow
Journal:  Crit Care       Date:  2015-08-13       Impact factor: 9.097

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.